Eli Lilly and Company (LLY) announced today that it has committed more than $5.3 billion to its Lebanon, Indiana, manufacturing site, more than doubling its investment. The funds will allow Lilly to expand its production of tirzepatide weight-loss and diabetes injections.

Brad Smith and Seana Smith discuss investors' push on this front and Goldman Sachs' 2030 projections for the industry.

For more expert insight and the latest market action, click here to watch this full episode of Morning Brief.

This article was written by Gabriel Roy